Comparison of Macular Pigment Optical Density in Glaucoma Patients and Healthy Subjects - A Prospective Diagnostic Study.
case-control study
glare
glaucoma
macular pigment optical density
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
07
2019
accepted:
27
02
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
To evaluate the relationship between macular pigment optical density (MPOD) and glaucoma. Forty-three patients with an established glaucoma diagnosis (25 females, 18 males, mean age 70 (range 34-84)) and 43 healthy controls (28 females, 15 males, mean age 62 (range 30-87)) were included in this prospective diagnostic case-control study. All subjects underwent detailed eye examination including ophthalmoscopy, best-corrected visual acuity, biomicroscopy, measurement of the axial length of the eye, objective refraction, lens status, central foveal thickness on spectral-domain optical coherence tomography (SD-OCT). In all glaucoma patients, a visual field assessment and a measurement of the retinal nerve fibre layer (RNFL) on SD-OCT were done. MPOD was determined using the macula pigment module of the Spectralis HRA+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany) at 0.51°, 1.02° and 1.99° retinal eccentricity using two-wavelength autofluorescence imaging. In the glaucoma group, the median of the visual field mean defect was 5.1 db (quartiles 3.0 and 13.5) and the mean RNFL-thickness global was 65.9 µm (SD ± 16.1). Median MPOD measured at 0.51°, 1.02° and 1.99° retinal eccentricity in the glaucoma group was 0.42 DU, 0.34 DU and 0.13 DU, in the control group 0.40 DU, 0.35 DU and 0.12 DU respectively. There was no statistically significant difference of median MPOD between glaucomatous and control eyes (p=0.510, 0.735, 0.481). No significant relation between MPOD at 1.02 retinal eccentricity and the presence of glare symptoms was found (p=0.948). However, age seems to correlate with median MPOD measured at 1.02 retinal eccentricity (p=0.017). There was no evidence for lower MPOD levels in our glaucoma patients; lower MPOD was not related to the presence of glare symptoms. However there seems to be a positive correlation between age and MPOD at 1.02° retinal eccentricity. To further investigate the relation between glare reported by glaucoma patients and glare disability linked to lower MPOD levels, additional studies are necessary that include both detailed inquiry of the quality of glare and a glare quantification and precise analysis of MPOD levels in glaucoma patients.
Identifiants
pubmed: 32308361
doi: 10.2147/OPTH.S224259
pii: 224259
pmc: PMC7140904
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1011-1017Informations de copyright
© 2020 Bruns et al.
Déclaration de conflit d'intérêts
Amelie Pielen reports grants from Niedersachsen Vorab, during the conduct of the study. The authors declare that they have no other conflicts of interest in this work.
Références
Retina. 2010 Sep;30(8):1282-93
pubmed: 20671587
Exp Eye Res. 2000 Sep;71(3):239-45
pubmed: 10973733
Br J Ophthalmol. 1999 Jul;83(7):867-77
pubmed: 10381676
Curr Eye Res. 2010 Apr;35(4):335-51
pubmed: 20373901
Eye (Lond). 2012 Aug;26(8):1052-7
pubmed: 22627475
Invest Ophthalmol Vis Sci. 2001 Feb;42(2):439-46
pubmed: 11157880
Exp Eye Res. 2007 Apr;84(4):718-28
pubmed: 17306793
Invest Ophthalmol Vis Sci. 2011 Oct 11;52(11):8016-24
pubmed: 21896850
Invest Ophthalmol Vis Sci. 1997 Aug;38(9):1802-11
pubmed: 9286269
Br J Ophthalmol. 1999 May;83(5):546-52
pubmed: 10216052
Vision Res. 1987;27(7):1077-83
pubmed: 3660662
Optom Vis Sci. 2007 Sep;84(9):859-64
pubmed: 17873771
Curr Opin Ophthalmol. 2007 Mar;18(2):110-4
pubmed: 17301611
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):47-50
pubmed: 11773011
Invest Ophthalmol Vis Sci. 1984 Jun;25(6):674-85
pubmed: 6724837
Oman J Ophthalmol. 2015 Jan-Apr;8(1):19-23
pubmed: 25709269
J Opt Soc Am A Opt Image Sci Vis. 1997 Jun;14(6):1187-96
pubmed: 9168592
J Optom. 2015 Oct-Dec;8(4):258-65
pubmed: 25697374
Vision Res. 2011 Mar 2;51(5):459-69
pubmed: 21237188
EXS. 1992;62:280-98
pubmed: 1450592
Br J Ophthalmol. 2013 Aug;97(8):994-8
pubmed: 23686328
Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1221-8
pubmed: 24614948
Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1565-74
pubmed: 16642363
Retina. 2014 May;34(5):920-8
pubmed: 24150241
Vision Res. 2010 Jun 18;50(13):1249-56
pubmed: 20394766
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):476-81
pubmed: 23211814
Nutrients. 2016 Jul 12;8(7):
pubmed: 27420092
Invest Ophthalmol Vis Sci. 1988 Jun;29(6):843-9
pubmed: 3372161
Eur J Ophthalmol. 2009 Sep-Oct;19(5):836-41
pubmed: 19787606